Peter Carroll, MD

Peter R. Carroll, MD, MPH

Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer; Taube Family Distinguished Professorship in Urology, UCSF

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF

Cancer Center Program Membership

Prostate Cancer

Phone: (415) 353-7171 (appts)

Box 1711, UCSF
San Francisco, CA 94143-1711

Physician Biography

UCSF Profiles

Research Summary

My main research interests include identifying clinical and pathologic determinants of prostate cancer recurrence, progression, and mortality; discovering novel biomarkers for prostate cancer diagnostics and prognostics; developing evidence-based guidelines for improved management of prostate cancer patients; and examining the impact of lifestyle on health-related quality of life and survivorship among men with prostate cancer. Since 1995, I have been PI of CaPSURE™, a national disease registry study of over 14,000 men with prostate cancer treated at 40+ sites. At UCSF, we have developed a novel program in clinical management of and research on active surveillance for men with low-burden prostate cancer. We are committed to reducing the burden of prostate cancer treatment (physical, psychological and monetary). In 2007, I and colleagues initiated the Prostate Cancer Active Surveillance Study (PASS), a large multi-institutional cohort of men on active surveillance, designed to examine quantitative metabolic, molecular, and physiologic imaging biomarkers and lifestyle factors as novel predictors of prostate cancer progression. We aim to better determine which patients may safely avoid radical treatment, while concurrently identifying men who may benefit from early treatment instead of active surveillance.

Research Funding

  • August 5, 1999 - May 31, 2023 - Cancer Center Support Grant , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: P30CA082103
  • September 30, 2008 - July 31, 2020 - UCSF KURe Career Development Program , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12DK083021
  • September 30, 2009 - August 31, 2012 - Effectiveness of Early Stage Prostate Cancer Treatment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: RC1CA146596
  • September 30, 2006 - August 31, 2012 - Male Reproductive Health Research Career Development Program , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12HD053943
  • September 25, 2000 - June 30, 2010 - UCSF PROSTATE CANCER SPORE , Principal Investigator . Sponsor: NIH, Sponsor Award ID: P50CA089520
  • June 10, 2003 - May 31, 2009 - Molecular Effects of Nutrition Supplements in Prostate , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA101042
  • May 5, 2006 - April 30, 2007 - Active Surveillance for Early Stage Prostate Cancer: Selection, Monitoring , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R13CA121759

Education

University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. Song H, Xu J, Velazquez-Arcelay K, Demirci A, Raizenne BL, Hsu SC, Choi J, Pham JH, Chen YA, Weinstein HNW, Salzman I, Tsui M, Akutagawa J, Adingo W, Goldschmidt E, Carroll PR, Hong JC, Heaphy CM, Cooperberg MR, Greenland N, Campbell JD, Huang FW. A single-cell and spatial atlas of prostate cancer reveals the combinatorial nature of gene modules underlying lineage plasticity and metastasis. bioRxiv. 2026 Mar 27. View on PubMed
  2. Shee K, Pace WA, Song JJ, Raizenne BL, Cowan JE, Wang L, Washington SL, Shinohara K, Nguyen HG, Carroll PR, Cooperberg MR. A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2026 Jan 30. View on PubMed
  3. Pace WA, Olshen A, Wang Y, Kenfield SA, Van Blarigan EL, Graff RE, Cowan J, Wang L, Tenggara I, Lopez K, Encabo K, Jones LW, Panchal N, Cooperberg MR, Carroll PR, Luke A, Pollak M, Chan JM. Inflammation and insulin profiles in men assigned to exercise vs. usual care for prostate cancer: results from the active surveillance exercise (ASX) randomized controlled trial. Cancer Causes Control. 2026 Jan 17; 37(2):22. View on PubMed
  4. Odisho AY, Liu AW, Pace WA, Carlisle MN, Krumm R, Cowan JE, Carroll PR, Cooperberg MR. Generative Artificial Intelligence Successfully Automates Data Extraction From Unstructured Magnetic Resonance Imaging Reports: Feasibility in Prostate Cancer Care. JCO Clin Cancer Inform. 2026 Jan; 10:e2400334. View on PubMed
  5. Carlisle MN, Pace WA, Liu AW, Krumm R, Cowan JE, Carroll PR, Cooperberg MR, Odisho AY. Development and Validation of a Generative Artificial Intelligence-Based Pipeline for Automated Clinical Data Extraction From Electronic Health Records: Technical Implementation Study. JMIR Bioinform Biotechnol. 2026 Jan 06; 7:e70708. View on PubMed
  6. Liu L, Lian L, Hao Y, Pace A, Kim E, Homsi N, Pershad Y, Lai L, Gracie T, Kishtagari A, Carroll PR, Bick AG, Odisho AY, Chung M, Yala A. Human level information extraction from clinical reports with finetuned language models. Sci Rep. 2025 Nov 24; 15(1):45239. View on PubMed
  7. Chen WS, Tuchayi AM, Sabbagh A, Kim I, Porter E, Ashraf-Ganjouei A, Li YR, Witztum A, Rajagopal A, Seyedin SN, Juarez R, Carroll PR, Feng FY, Small EJ, Hope TA, Hong JC. Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer. JNCI Cancer Spectr. 2025 Nov 03; 9(6). View on PubMed
  8. Greenland NY, Cowan JE, Ding CC, Sirohi D, Cooperberg MR, Carroll PR, Simko JP, Stohr BA, Zhang L, Chan E. Correlation of unfavourable and favourable histology at radical prostatectomy with Decipher scores and freedom from biochemical recurrence. Histopathology. 2026 Feb; 88(3):605-614. View on PubMed
  9. McKenney JK, Brooks JD, Nguyen JK, Ding CKC, Newcomb LF, Myles JL, Alaghehbandan R, Przybycin CG, Chan E, Simko JP, Greenland NY, Schwen Z, Weight CJ, Cooperberg MR, Carroll PR. In reply to: 'Prostate cancer with favorable histology is not synonymous with prostate cancer indolence'. Histopathology. 2026 Jan; 88(2):549-550. View on PubMed
  10. Raizenne BL, Shee K, Cowan JE, Carroll PR, Cooperberg MR. Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients. Eur Urol Oncol. 2025 Oct; 8(5):1221-1226. View on PubMed
  11. Shee K, Pace WA, Liu AW, Cowan JE, Subramanyam V, Agapito C, Washington SL, Cooperberg MR, Carroll PR, Shinohara K, Nguyen HG. Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer. Eur Urol Focus. 2025 Nov; 11(6):869-875. View on PubMed
  12. Shee K, Song JJ, Cowan JE, Wang L, Nie J, Chappidi M, Washington SL, Nguyen HG, Cooperberg MR, Shinohara K, Carroll PR. The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era. Eur Urol Oncol. 2025 Aug; 8(4):1094-1100. View on PubMed
  13. Li KD, Carlisle MN, Jarosek S, Patel HV, Faris A, Elliott SP, Cooperberg MR, Carroll PR, Breyer BN. Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data. Eur Urol. 2026 Jan; 89(1):8-11. View on PubMed
  14. Shee K, Cowan JE, Ding CC, Wang L, Pace W, Greenland N, Simko JP, Washington SL, Shinohara K, Nguyen HG, Cooperberg MR, Carroll PR. Gleason Grade Group 3 Represents a Spectrum of Disease: Results from a Large Institutional Cohort. Eur Urol Focus. 2026 Jan; 12(1):61-69. View on PubMed
  15. Shee K, Cedars BE, Wang L, Kenfield SA, Cowan JE, Tolstykh I, Langlais CS, Pace WA, Broering JM, Carroll PR, Chan JM, Van Blarigan EL. Multivitamin Use After Prostate Cancer Diagnosis Is Associated with Lower Risk of Recurrence: A Prospective Cohort Study from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Eur Urol Oncol. 2025 Aug; 8(4):1003-1009. View on PubMed
  16. Palmer NR, Carroll PR, Washington SL. Time is on our side - rethinking the concept of time to treatment for prostate cancer. Nat Rev Urol. 2025 May; 22(5):251-252. View on PubMed
  17. Chappidi MR, Newcomb LF, Zheng Y, Liu M, Schenk JM, Zhu K, de la Calle CM, Brooks JD, Carroll PR, Dash A, Filson CP, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Wagner AA, Nelson PS, Lin DW. Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance Study. J Urol. 2025 09; 214(3):251-258. View on PubMed
  18. Kuzuoglu-Ozturk D, Nguyen HG, Xue L, Figueredo E, Subramanyam V, Liu I, Bonitto K, Noronha A, Dabrowska A, Cowan JE, Oses-Prieto JA, Burlingame AL, Worland ST, Carroll PR, Ruggero D. Small-molecule RNA therapeutics to target prostate cancer. Cancer Cell. 2025 May 12; 43(5):841-855.e8. View on PubMed
  19. Fakunle MO, Cowan JE, Washington SL, Shinohara K, Nguyen HG, Carroll PR. Targeted Biopsy Is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2025 01; 213(1):34-39. View on PubMed
  20. Carroll PR. Legends in Urology v31I05. Can J Urol. 2024 Oct; 31(5):11974-11976. View on PubMed

Go to UCSF Profiles, powered by CTSI